Combining inhibitors of these 2 targets has proven effective in other cancer cell systems such as in lung cancer cells [74], ovarian cancer cells [75] and also in murine xenografts models where combined PI3K/mTOR and JAK inhibitors showing potent efficacy of Philadelphia-like acute lymphoblastic leukemia [76] and should be tested in glioblastoma, along with other combinations suggested by the current data. The gene discussed is PIK3CA; the disease is ovarian carcinoma.